Corient Private Wealth LLC Grows Holdings in Geron Co. (NASDAQ:GERN)

Corient Private Wealth LLC lifted its position in shares of Geron Co. (NASDAQ:GERN) by 58.7% during the 4th quarter, HoldingsChannel reports. The fund owned 37,585 shares of the biopharmaceutical company’s stock after purchasing an additional 13,896 shares during the period. Corient Private Wealth LLC’s holdings in Geron were worth $133,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of GERN. RTW Investments LP acquired a new position in Geron in the 3rd quarter worth about $200,268,000. State Street Corp grew its holdings in Geron by 28.4% in the third quarter. State Street Corp now owns 28,961,671 shares of the biopharmaceutical company’s stock valued at $131,486,000 after purchasing an additional 6,413,204 shares during the period. Janus Henderson Group PLC increased its position in shares of Geron by 140.0% in the third quarter. Janus Henderson Group PLC now owns 22,565,846 shares of the biopharmaceutical company’s stock valued at $102,193,000 after buying an additional 13,163,889 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Geron by 1.8% during the 3rd quarter. Geode Capital Management LLC now owns 13,067,999 shares of the biopharmaceutical company’s stock worth $59,339,000 after buying an additional 231,178 shares during the period. Finally, Wellington Management Group LLP raised its stake in shares of Geron by 4.7% during the 3rd quarter. Wellington Management Group LLP now owns 12,662,404 shares of the biopharmaceutical company’s stock worth $57,487,000 after buying an additional 570,580 shares during the period. 73.71% of the stock is currently owned by institutional investors and hedge funds.

Geron Price Performance

NASDAQ:GERN opened at $1.48 on Wednesday. Geron Co. has a one year low of $1.45 and a one year high of $5.34. The stock has a market cap of $942.62 million, a PE ratio of -4.63 and a beta of 0.54. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.74 and a current ratio of 2.89. The stock has a 50 day moving average price of $2.24 and a 200 day moving average price of $3.33.

Geron (NASDAQ:GERN) last issued its earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.04). Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. The company had revenue of $47.54 million during the quarter, compared to analysts’ expectations of $45.29 million. Equities research analysts expect that Geron Co. will post -0.25 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on GERN. Stifel Nicolaus cut their price target on shares of Geron from $8.00 to $4.00 and set a “buy” rating for the company in a report on Thursday, February 27th. HC Wainwright reiterated a “neutral” rating on shares of Geron in a research report on Wednesday, March 12th. Barclays restated an “overweight” rating and set a $4.00 price target (down previously from $9.00) on shares of Geron in a research report on Thursday, February 27th. B. Riley cut Geron from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $3.50 to $2.00 in a report on Thursday, February 27th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $5.00 price objective on shares of Geron in a research note on Wednesday, March 12th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Geron has an average rating of “Moderate Buy” and an average price target of $5.75.

Geron Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.